We are live on ! Find out more
NAVB

Navidea Biopharmaceuticals Inc.
NAVB

Delisted

NAVB was delisted on the 5th of October, 2023.

Back to rankings

56 hedge funds and large institutions have $5.76M invested in Navidea Biopharmaceuticals Inc. in 2017 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 13 increasing their positions, 13 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

26% more call options, than puts

Call options by funds: $24K | Put options by funds: $19K

8% more funds holding

Funds holding: 52 → 56 (+4)

0% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 13

23% less capital invested

Capital invested by funds: $7.5M → $5.76M (-$1.74M)

Holders
56
Holders Change
+4
Holders Change %
+7.69%
% of All Funds
1.4%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
13
Reduced
13
Closed
–
Calls
$24K
Puts
$19K
Net Calls
+$5K
Net Calls Change
+$18K

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$93.4K
2
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
+$33.6K
3
Wells Fargo
Wells Fargo
California
+$23.9K
4
Jane Street
Jane Street
New York
+$19.9K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$18.4K

Top Sellers

Rank Fund Capital Flow
1
SFS
Sowell Financial Services
Arkansas
-$347K
2
SIM
Spark Investment Management
New York
-$105K
3
Millennium Management
Millennium Management
New York
-$104K
4
TRCT
Tower Research Capital (TRC)
New York
-$18.4K
5
Goldman Sachs
Goldman Sachs
New York
-$15.5K
Name Holding Trade Value Shares
Change 		Change in
Stake
SWP
26
Stratos Wealth Partners
Ohio
$23K +$3.31K +390 +16%
SW
27
SVB Wealth
Massachusetts
$19K – – –
Tudor Investment Corp
28
Tudor Investment Corp
Connecticut
$19K – – –
Citadel Advisors
29
Citadel Advisors
Florida
$17K +$4.29K +506 +33%
Bank of America
30
Bank of America
North Carolina
$15K -$2.3K -271 -13%
Cambridge Investment Research Advisors
31
Cambridge Investment Research Advisors
Iowa
$14K -$25 -3 -0.2%
Commonwealth Equity Services
32
Commonwealth Equity Services
Massachusetts
$13K -$636 -75 -5%
LFG
33
LifePlan Financial Group
Ohio
$12K – – –
TSS
34
Two Sigma Securities
New York
$10K +$10.1K +1,188 New
JCM
35
Jacobi Capital Management
Pennsylvania
$9K – – –
SIAS
36
Shine Investment Advisory Services
Colorado
$8K – – –
LA
37
Lynch & Associates
Indiana
$7K – – –
RJA
38
Raymond James & Associates
Florida
$7K – – –
WS
39
Wedbush Securities
California
$7K +$6.78K +800 New
Group One Trading
40
Group One Trading
Illinois
$6K -$3.73K -440 -36%
Wolverine Trading
41
Wolverine Trading
Illinois
$6K -$169 -20 -3%
Ameriprise
42
Ameriprise
Minnesota
$5K – – –
B
43
Bailard
California
$4K – – –
Royal Bank of Canada
44
Royal Bank of Canada
Ontario, Canada
$4K +$34 +4 +0.8%
MML Investors Services
45
MML Investors Services
Massachusetts
$4K +$4.24K +500 New
VF
46
Virtu Financial
New York
$4K +$4.5K +531 New
TRCT
47
Tower Research Capital (TRC)
New York
$2K -$18.4K -2,167 -88%
AG
48
Advisor Group
Arizona
$2K – – –
ASN
49
Advisory Services Network
Georgia
$2K +$110 +13 +5%
IA
50
IFP Advisors
Florida
$1K -$1.27K -150 -60%
1
2
3

NAVB Hedge Fund Activity: Q3 2017 in Review

56 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Navidea Biopharmaceuticals Inc. (NAVB) for Q3 2017, worth a combined $5.76M — down 23% from $7.5M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new NAVB positions and 0 closed out — a net gain of 5 holders — while 13 added to existing stakes and 13 trimmed.

The largest buyer was UBS Group, adding an estimated $93.4K. The largest seller was Sowell Financial Services, cutting an estimated $347K.

  • 56 institutional investors held Navidea Biopharmaceuticals Inc. (NAVB) as of Q3 2017, up from 52 in Q2 2017.
  • Funds reported $5.76M of Navidea Biopharmaceuticals Inc. stock for Q3 2017, down 23% quarter-over-quarter.
  • 5 funds opened new Navidea Biopharmaceuticals Inc. positions in Q3 2017 and 0 closed out, a net change of +5 holders.
  • The largest Navidea Biopharmaceuticals Inc. buyer in Q3 2017 was UBS Group, an estimated $93.4K added.
  • The largest Navidea Biopharmaceuticals Inc. seller in Q3 2017 was Sowell Financial Services, an estimated $347K sold.

Based on aggregated 13F filings for Q3 2017.